Compare Stocks: HURA, VALN, EIKN, and RGNX

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
EIKN Eikon Therapeutics	$11.05 +7.0%	$10.07	$7.90 ▼ $17.40	$598.24M	N/A	317,371 shs	637,716 shs
HURA TuHURA Biosciences	$2.47 +7.4%	$2.28	$0.41 ▼ $3.43	$157.30M	-0.01	235,478 shs	317,089 shs
RGNX REGENXBIO	$10.77 +1.0%	$10.42	$5.45 ▼ $16.19	$710.63M	0.94	1.57 million shs	792,276 shs
VALN Valneva	$7.13 +26.2%	$5.24	$4.75 ▼ $12.25	$676.54M	1.77	27,253 shs	2.87 million shs

7 Best Space Stocks to Own in 2026

The space race is growing fast, and you don’t have to have gotten in early on SpaceX to profit. This report shows seven space stocks you can buy today that may grow as rockets, satellites, defense, space internet, and new space technology become more important.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
EIKN Eikon Therapeutics	0.00%	+18.95%	+11.06%	-16.60%	+1,104,999,900.00%
HURA TuHURA Biosciences	0.00%	+15.96%	+11.26%	+6.93%	-13.03%
RGNX REGENXBIO	0.00%	+0.47%	-3.84%	+88.29%	+20.60%
VALN Valneva	0.00%	+34.53%	+40.35%	+25.53%	-36.11%

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
EIKN Eikon Therapeutics	$11.05 +7.0%	$10.07	$7.90 ▼ $17.40	$598.24M	N/A	317,371 shs	637,716 shs
HURA TuHURA Biosciences	$2.47 +7.4%	$2.28	$0.41 ▼ $3.43	$157.30M	-0.01	235,478 shs	317,089 shs
RGNX REGENXBIO	$10.77 +1.0%	$10.42	$5.45 ▼ $16.19	$710.63M	0.94	1.57 million shs	792,276 shs
VALN Valneva	$7.13 +26.2%	$5.24	$4.75 ▼ $12.25	$676.54M	1.77	27,253 shs	2.87 million shs

7 Best Space Stocks to Own in 2026

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
EIKN Eikon Therapeutics	0.00%	+18.95%	+11.06%	-16.60%	+1,104,999,900.00%
HURA TuHURA Biosciences	0.00%	+15.96%	+11.26%	+6.93%	-13.03%
RGNX REGENXBIO	0.00%	+0.47%	-3.84%	+88.29%	+20.60%
VALN Valneva	0.00%	+34.53%	+40.35%	+25.53%	-36.11%

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
EIKN Eikon Therapeutics	2.38	Hold	$25.00	126.24% Upside
HURA TuHURA Biosciences	2.67	Moderate Buy	$9.00	264.37% Upside
RGNX REGENXBIO	2.62	Moderate Buy	$23.73	120.31% Upside
VALN Valneva	2.33	Hold	$11.98	68.02% Upside

Current Analyst Ratings Breakdown

Latest HURA, VALN, EIKN, and RGNX Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
8/14/2026	EIKN Eikon Therapeutics	Wedbush Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Lower Price Target	Underperform	$5.00 ➝ $4.00
8/12/2026	RGNX REGENXBIO	Zacks Research Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Strong Sell ➝ Hold
8/11/2026	VALN Valneva	TD Cowen Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Initiated Coverage	Buy	$12.00
8/11/2026	VALN Valneva	TD Cowen Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Initiated Coverage	Buy	$12.00
8/10/2026	RGNX REGENXBIO	HC Wainwright Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Lower Price Target	Buy	$26.00 ➝ $23.00
8/7/2026	RGNX REGENXBIO	Morgan Stanley Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Overweight	$18.00
8/7/2026	RGNX REGENXBIO	Barclays Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Downgrade	Overweight ➝ Hold
8/7/2026	RGNX REGENXBIO	Barclays Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Overweight ➝ Equal Weight	$12.00
8/3/2026	EIKN Eikon Therapeutics	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Sell (E-) ➝ Sell (E)
7/17/2026	HURA TuHURA Biosciences	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Sell (E+)
7/14/2026	RGNX REGENXBIO	Zacks Research Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Downgrade	Hold ➝ Strong Sell

(Data available from 8/16/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
EIKN Eikon Therapeutics	N/A	N/A	N/A	N/A	N/A	N/A
HURA TuHURA Biosciences	N/A	N/A	N/A	N/A	$0.34 per share	N/A
RGNX REGENXBIO	$170.44M	4.17	N/A	N/A	$1.09 per share	9.88
VALN Valneva	$197.56M	3.42	N/A	N/A	$1.39 per share	5.13

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
EIKN Eikon Therapeutics	-$324.25M	-$2.46	N/A	N/A	N/A	N/A	N/A	N/A	N/A
HURA TuHURA Biosciences	-$30.05M	-$0.61	N/A	N/A	N/A	N/A	-156.12%	-105.38%	N/A
RGNX REGENXBIO	-$193.88M	-$3.79	N/A	N/A	N/A	-112.58%	-220.07%	-46.04%	N/A
VALN Valneva	-$130.33M	-$2.11	N/A	9.26	N/A	-110.33%	-142.99%	-39.11%	N/A

Latest HURA, VALN, EIKN, and RGNX Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
8/13/2026	Q2 2026	EIKN Eikon Therapeutics	-$1.61	-$1.63	-$0.02	-$1.63	N/A	N/A
8/13/2026	Q2 2026	HURA TuHURA Biosciences	-$0.1533	-$0.14	+$0.0133	-$0.14	N/A	N/A
8/13/2026	Q2 2026	VALN Valneva	-$0.1886	-$0.40	-$0.2114	-$0.38	$48.21 million	$39.37 million
8/6/2026	Q2 2026	RGNX REGENXBIO	$0.0787	$0.43	+$0.3513	$0.43	$97.63 million	$108.02 million

Compare Dividends

Company	Annual Payout	Dividend Yield	5-Year Annualized Dividend Growth	Payout Ratio	Years of Consecutive Growth
EIKN Eikon Therapeutics	N/A	N/A	N/A	N/A	N/A
HURA TuHURA Biosciences	N/A	N/A	N/A	N/A	N/A
RGNX REGENXBIO	N/A	N/A	N/A	N/A	N/A
VALN Valneva	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
EIKN Eikon Therapeutics	N/A	11.75	11.75
HURA TuHURA Biosciences	N/A	1.15	1.15
RGNX REGENXBIO	N/A	2.86	2.86
VALN Valneva	2.14	2.14	1.60

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
EIKN Eikon Therapeutics	N/A
HURA TuHURA Biosciences	0.62%
RGNX REGENXBIO	88.08%
VALN Valneva	11.39%

Insider Ownership

Company	Insider Ownership
EIKN Eikon Therapeutics	N/A
HURA TuHURA Biosciences	6.06%
RGNX REGENXBIO	14.22%
VALN Valneva	14.91%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
EIKN Eikon Therapeutics	384	54.14 million	N/A	N/A
HURA TuHURA Biosciences	N/A	63.68 million	59.82 million	N/A
RGNX REGENXBIO	370	66.01 million	56.63 million	Optionable
VALN Valneva	700	94.89 million	80.74 million	Not Optionable

HURA, VALN, EIKN, and RGNX Headlines

Recent News About These Companies

Pfizer, Valneva Lyme vaccine starts review in Europe

August 15 at 7:28 PM | pharmaphorum.comP

Valneva Shares Climb After Lyme Disease Vaccine Receives EMA Application Acceptance

August 15 at 2:27 PM | marketwatch.com

Update: Valneva Shares Gain as Lyme Vaccine Candidate Gets EMA Review

August 15 at 2:27 PM | finance.yahoo.com

Valneva (NASDAQ:VALN) Issues Earnings Results, Misses Expectations By $0.17 EPS

August 14 at 3:55 PM | marketbeat.com

Valneva (NASDAQ:VALN) Sees Strong Trading Volume - What's Next?

August 14 at 11:39 AM | marketbeat.com

A Lyme disease vaccine may finally be on the way. Why did it take so long?

August 14 at 8:46 AM | nationalpost.comN

EU to study potential vaccine for Lyme disease: companies

August 14 at 8:46 AM | yahoo.com

Valneva SE 2026 Q2 - Results - Earnings Call Presentation

August 14 at 3:01 AM | seekingalpha.com

Valneva (NASDAQ:VALN) Research Coverage Started at TD Cowen

August 14 at 1:54 AM | americanbankingnews.com

Pfizer and Valneva's Lyme Disease Vaccine Candidate Marketing Authorization Application Validated by European Medicines Agency

August 14 at 1:00 AM | globenewswire.com

Valneva SE (INRLF) (H1 2026) Earnings Call Highlights: Strategic Pivot and Lyme Vaccine ...

August 13 at 10:38 PM | finance.yahoo.com

Valneva outlines $145M-$160M 2026 revenue guidance while Pfizer targets Lyme decisions within 12 months

August 13 at 10:38 PM | seekingalpha.com

Valneva SE (VALN) Q2 2026 Earnings Call Transcript

August 13 at 7:00 PM | seekingalpha.com

Valneva Q2 Earnings Call Highlights

August 13 at 3:03 PM | marketbeat.com

VALNEVA SE: Valneva Reports Half Year 2026 Financial Results and Provides Corporate Updates

August 13 at 7:37 AM | finanznachrichten.de

Valneva Reports Half Year 2026 Financial Results and Provides Corporate Updates

August 13, 2026 | globenewswire.com

Valneva (NASDAQ:VALN) Rating Increased to Strong-Buy at TD Cowen

August 12, 2026 | marketbeat.com

Valneva (NASDAQ:VALN) Shares Gap Up - Here's Why

August 11, 2026 | marketbeat.com

Valneva (VALN) to Announce Quarterly Earnings on Thursday

August 6, 2026 | americanbankingnews.com

Valneva (VALN) to Release Quarterly Earnings on Thursday

August 6, 2026 | marketbeat.com

Valneva SE Sponsored ADR (NASDAQ:VALN) Given Average Recommendation of "Hold" by Analysts

August 5, 2026 | americanbankingnews.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

HURA, VALN, EIKN, and RGNX Company Descriptions

Eikon Therapeutics NASDAQ:EIKN

$11.05 +0.72 (+6.97%)

Closing price 08/14/2026 04:00 PM Eastern

Extended Trading

$11.04 -0.01 (-0.09%)

As of 08/14/2026 07:34 PM Eastern

We are a late-stage clinical biopharmaceutical company dedicated to building a global, fully-integrated organization developing important, innovative medicines to address serious unmet medical needs. We are led by world-renowned drug developers Dr. Roger M. Perlmutter, M.D., Ph.D., and Dr. Roy Baynes, M.D., Ph.D. Our vision is to become a generational leader, by purposefully integrating traditional biology research with advanced engineering to develop better medicines faster. Our initial focus is oncology, where we are advancing a pipeline of drug candidates targeting areas of high unmet need in large indications. We believe our product candidates reflect strong scientific and clinical potential and could eventually become critical medicines in the treatment paradigm of various cancers. Our Chair and Chief Executive Officer, Dr. Roger M. Perlmutter, M.D., Ph.D., and our Chief Medical Officer, Dr. Roy Baynes, M.D., Ph.D., together have a proven track record of identifying, developing, and commercializing some of the most impactful drugs ever brought to market, including pembrolizumab, currently the world’s best-selling oncology therapeutic and arguably the most important anti-neoplastic agent ever introduced into clinical practice. While Drs. Perlmutter and Baynes’ track records do not provide a guarantee of future clinical success, and any products developed by us may not achieve the regulatory or commercial success of products that Drs. Perlmutter and Baynes were previously involved in developing, their experience provides valuable insight and strategic guidance to our drug development efforts. Our broader leadership team consists of former senior leaders at global pharmaceutical companies, who have successfully collaborated across several decades on the discovery, development, and commercialization of over 100 new molecular entities. Our strategy centers around deploying our technology platform, including our proprietary single molecule tracking, or SMT, system, to develop internally-derived novel therapies, while also leveraging the deep expertise of our management team to opportunistically in-license promising assets. Our most advanced product candidate, EIK1001, a toll-like receptor, or TLR, 7/8 dual-agonist, is currently in a global Phase 2/3 registrational trial in combination with pembrolizumab for the treatment of patients with advanced melanoma. This Phase 2/3 trial is designed to proceed to completion, subject to interim analysis by a data monitoring committee, and to form the basis for registration. We are also evaluating EIK1001 in combination with both pembrolizumab and histology appropriate chemotherapy for the treatment of patients with non-small cell lung cancer, or NSCLC, in a Phase 2 trial, as well as a Phase 2/3 registrational trial for which we recently initiated site selection. We are also conducting Phase 1/2 trials of each of our selective PARP1 inhibitor product candidates, EIK1003 and EIK1004, in ovarian, breast, prostate, and pancreatic cancers and, specifically with the brain-penetrant candidate EIK1004, to address brain metastases and primary brain malignancies. In addition, we have recently initiated a Phase 1/2 trial in patients with advanced solid tumors for EIK1005, our Werner, or WRN, helicase inhibitor that emerged through internal research using our technology platform, which will ultimately be evaluated for the treatment of patients with microsatellite instability-high, or MSI-high, tumors. We were incorporated in Delaware in July 2019. Our principal executive offices are located in Millbrae, California.

TuHURA Biosciences NASDAQ:HURA

$2.47 +0.17 (+7.39%)

Closing price 08/14/2026 04:00 PM Eastern

Extended Trading

$2.46 -0.01 (-0.36%)

As of 08/14/2026 07:36 PM Eastern

TuHURA Biosciences, Inc. (NASDAQ: HURA) is a Phase 3 registration-stage immuno-oncology company developing novel technologies to overcome resistance to cancer immunotherapy. TuHURA's lead innate immune response agonist candidate, IFx-2.0, is designed to overcome primary resistance to checkpoint inhibitors. TuHURA is preparing to initiate a single randomized placebo-controlled Phase 3 registration trial of IFx-2.0 administered as an adjunctive therapy to Keytruda® (pembrolizumab) in first line treatment for advanced or metastatic Merkel Cell Carcinoma. In addition to its innate immune response agonist candidates, TuHURA is leveraging its Delta receptor technology to develop first-in-class bi-specific ADCs, and PDCs targeting Myeloid Derived Suppressor Cells to inhibit their immune suppressing effects on the tumor microenvironment to prevent T cell exhaustion and acquired resistance to checkpoint inhibitors and cellular therapies.

REGENXBIO NASDAQ:RGNX

$10.77 +0.11 (+1.03%)

Closing price 08/14/2026 04:00 PM Eastern

Extended Trading

$10.79 +0.02 (+0.20%)

As of 08/14/2026 07:54 PM Eastern

REGENXBIO Inc., a clinical-stage biotechnology company, provides gene therapies that deliver functional genes to cells with genetic defects in the United States. Its gene therapy product candidates are based on NAV Technology Platform, a proprietary adeno-associated virus gene delivery platform. The company's products in pipeline includes ABBV-RGX-314 for the treatment of wet age-related macular degeneration, diabetic retinopathy, and other chronic retinal diseases; and RGX-202, which is in Phase I/II clinical trial for the treatment of Duchenne muscular dystrophy. It also develops RGX-121 for the treatment of mucopolysaccharidosis type II that is in Phase III clinical trial; RGX-111 for treating mucopolysaccharidosis type I; RGX-181 for the treatment of late infantile neuronal ceroid lipofuscinosis type II; and RGX-381 to treat the ocular manifestations of CLN2 disease. In addition, the company licenses its NAV Technology Platform to other biotechnology and pharmaceutical companies. Further, it has a collaboration and license agreement with AbbVie Global Enterprises Ltd. to develop ABBV-RGX-314 outside the United States. REGENXBIO Inc. was incorporated in 2008 and is headquartered in Rockville, Maryland.

Valneva NASDAQ:VALN

$7.13 +1.48 (+26.19%)

Closing price 08/14/2026 04:00 PM Eastern

Extended Trading

$6.88 -0.26 (-3.58%)

As of 08/14/2026 07:59 PM Eastern

Valneva SE, a specialty vaccine company, develops, manufactures, and commercializes prophylactic vaccines for infectious diseases with unmet needs. It offers IXIARO, an inactivated Vero cell culture-derived Japanese encephalitis vaccine indicated for active immunization against Japanese encephalitis; DUKORAL, an oral vaccine for the prevention of diarrhea caused by Vibrio cholera and/or heat-labile toxin producing enterotoxigenic Escherichia coli bacterium; IXCHIQ, a single-dose, live-attenuated vaccine for the prevention of disease caused by chikungunya virus; and VLA2001, an inactivated whole-virus COVID-19 vaccine. The company also develops VLA15, a vaccine candidate, which is in Phase III clinical trial against Borrelia, the bacterium that causes Lyme disease; VLA1553, a vaccine candidate, which is in Phase III clinical trial against the chikungunya virus; VLA1554, a vaccine candidate targeting human metapneumovirus; and VLA2112, a vaccine candidate to treat patients with epstein-barr virus. It sells its products in the United States, Canada, Germany, Austria, Nordics, the United Kingdom, France, rest of European countries, and internationally. Valneva SE has collaborations with Pfizer, Inc. to co-develop and commercialize its Lyme disease vaccine; and Instituto Butantan for the development, manufacturing, and marketing of single-shot chikungunya vaccine. The company was founded in 1998 and is based in Saint-Herblain, France.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest HURA, VALN, EIKN, and RGNX Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest HURA, VALN, EIKN, and RGNX Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

HURA, VALN, EIKN, and RGNX Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

HURA, VALN, EIKN, and RGNX Company Descriptions

Eikon Therapeutics NASDAQ:EIKN

TuHURA Biosciences NASDAQ:HURA

REGENXBIO NASDAQ:RGNX

Valneva NASDAQ:VALN

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest HURA, VALN, EIKN, and RGNX Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest HURA, VALN, EIKN, and RGNX Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

HURA, VALN, EIKN, and RGNX Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

HURA, VALN, EIKN, and RGNX Company Descriptions

Eikon Therapeutics NASDAQ:EIKN

TuHURA Biosciences NASDAQ:HURA

REGENXBIO NASDAQ:RGNX

Valneva NASDAQ:VALN

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools